{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:29:59Z","timestamp":1790386199678,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014837","name":"Rudolf-Ackermann-Stiftung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014837","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Vaccination against <jats:italic>Streptococcus pneumoniae<\/jats:italic> is recommended in transplant recipients to reduce the morbidity and mortality from invasive pneumococcal disease. Previous studies indicate that transplant recipients can produce specific antibodies after vaccination with the 13-valent pneumococcal conjugate vaccine Prevenar 13 (PCV13) or the pneumococcal polysaccharide vaccine Pneumovax 23 (PPSV23). National guidelines recommend sequential vaccination with PCV13 followed by PPSV23 in kidney transplant patients. However, there are currently no data on the serological response in kidney transplant recipients, who received a sequential vaccination with PCV13 and PPSV23.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the current study, we sequentially vaccinated 46 kidney transplant recipients with PCV13 and PPSV23 and determined global and serotype-specific anti-pneumococcal antibody responses in the year following vaccination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serotype-specific and global anti-pneumococcal antibody concentrations were significantly higher compared to baseline. We observed that serotype-specific antibody responses varied by serotype (between 2.2- and 2.9-fold increase after 12\u00a0months). The strongest responses after 12\u00a0months were detected against the serotypes 9N (2.9-fold increase) and 14 (2.8-fold increase). Global antibody responses also varied with respect to immunoglobulin class. IgG2 revealed the highest increase (2.7-fold), IgM the lowest (1.7-fold). Sequential vaccination with both vaccines achieved higher antibody levels in comparison with a historical cohort studied at our institute, that was vaccinated with PCV13 alone. During the 12-months follow-up period, none of the patients developed pneumococcal-associated pneumonia or vaccination-related allograft rejection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, we strongly recommend sequential vaccination over single immunization in kidney transplant recipients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-023-02054-3","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T04:01:43Z","timestamp":1685160103000},"page":"1703-1716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients"],"prefix":"10.1007","volume":"51","author":[{"given":"Nils","family":"M\u00fclling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"van de Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"V\u00f6lk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich Wilhelm","family":"Aufderhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalbert","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"2054_CR1","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","volume":"158","author":"JA Ramirez","year":"2020","unstructured":"Ramirez JA, et al. Treatment of community-acquired pneumonia in immunocompromised adults. Chest. 2020;158:1896\u2013911.","journal-title":"Chest"},{"key":"2054_CR2","doi-asserted-by":"crossref","unstructured":"del Garc\u00eda-Su\u00e1rez M, V\u00e1zquez F, M\u00e9ndez FJ. Streptococcus pneumoniae virulence factors and their clinical impact: An update. Enferm Infecc Microbiol Clin. 2006;24:512\u20137.","DOI":"10.1157\/13092469"},{"key":"2054_CR3","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(09)61114-4","volume":"374","author":"T van der Poll","year":"2009","unstructured":"van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. The Lancet. 2009;374:1543\u201356.","journal-title":"The Lancet"},{"key":"2054_CR4","doi-asserted-by":"crossref","unstructured":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61: 816\u20139.","DOI":"10.1111\/ajt.12073"},{"key":"2054_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJM Bonten","year":"2015","unstructured":"Bonten MJM, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med. 2015;372:1114\u201325.","journal-title":"N Engl J Med"},{"key":"2054_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00103-020-03123-w","volume":"63","author":"H-J Laws","year":"2020","unstructured":"Laws H-J, et al. Impfen bei Immundefizienz. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2020;63:588\u2013644.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"2054_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1586\/14789450.2015.1108844","volume":"12","author":"M Bittaye","year":"2015","unstructured":"Bittaye M, Cash P. Streptococcus pneumoniae proteomics: determinants of pathogenesis and vaccine development. Expert Rev Proteom. 2015;12:607\u201321.","journal-title":"Expert Rev Proteom"},{"key":"2054_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12866","volume":"20","author":"C Dendle","year":"2018","unstructured":"Dendle C, et al. Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis. 2018;20: e12866.","journal-title":"Transpl Infect Dis"},{"key":"2054_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/TP.0b013e3181ca56f8","volume":"89","author":"L Danziger-Isakov","year":"2010","unstructured":"Danziger-Isakov L, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation. 2010;89:838\u201344.","journal-title":"Transplantation"},{"key":"2054_CR10","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3390\/vaccines9121438","volume":"9","author":"A G\u00e4ckler","year":"2021","unstructured":"G\u00e4ckler A, et al. Establishment of an ELISpot assay to detect cellular immunity against S. pneumoniae in vaccinated kidney transplant recipients. Vaccines. 2021;9:1438.","journal-title":"Vaccines"},{"key":"2054_CR11","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/j.vaccine.2020.02.088","volume":"38","author":"S Oesterreich","year":"2020","unstructured":"Oesterreich S, et al. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. Vaccine. 2020;38:3339\u201350.","journal-title":"Vaccine"},{"key":"2054_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/TP.0b013e318250fc8c","volume":"94","author":"M Lindemann","year":"2012","unstructured":"Lindemann M, et al. Long-term response to vaccination against pneumococcal antigens in kidney transplant recipients. Transplantation. 2012;94:50\u20136.","journal-title":"Transplantation"},{"key":"2054_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/TP.0b013e3181f5d878","volume":"90","author":"M Lindemann","year":"2010","unstructured":"Lindemann M, et al. Immunity to pneumococcal antigens in kidney transplant recipients. Transplantation. 2010;90:1463\u20137.","journal-title":"Transplantation"},{"key":"2054_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17:204.","journal-title":"Crit Care"},{"key":"2054_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/21645515.2018.1509648","volume":"15","author":"L Huang","year":"2019","unstructured":"Huang L, et al. A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly. Hum Vaccin Immunother. 2019;15:249\u201355.","journal-title":"Hum Vaccin Immunother"},{"key":"2054_CR16","doi-asserted-by":"crossref","unstructured":"Lindemann M, et al. Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients. Vaccines. 2019;7:84.","DOI":"10.3390\/vaccines7030084"},{"key":"2054_CR17","first-page":"202","volume":"10","author":"U Schauer","year":"2003","unstructured":"Schauer U, et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagn Lab Immunol. 2003;10:202\u20137.","journal-title":"Clin Diagn Lab Immunol"},{"key":"2054_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plabm.2016.02.004","volume":"5","author":"AR Parker","year":"2016","unstructured":"Parker AR, Allen S, Harding S. Concentration of anti-pneumococcal capsular polysaccharide IgM, IgG and IgA specific antibodies in adult blood donors. Pract Lab Medicine. 2016;5:1\u20135.","journal-title":"Pract Lab Medicine"},{"key":"2054_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/cix419","volume":"65","author":"AMM van Deursen","year":"2017","unstructured":"van Deursen AMM, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the community-acquired pneumonia immunization trial in adults (CAPiTA). Clin Infect Dis. 2017;65:787\u201395.","journal-title":"Clin Infect Dis"},{"key":"2054_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMra2014530","volume":"385","author":"S Hariharan","year":"2021","unstructured":"Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021;385:729\u201343.","journal-title":"N Engl J Med"},{"key":"2054_CR21","unstructured":"Prevention CfDCa. Pneumococcal vaccination: summary of who and when to vaccinate. 2023 February 13, 2023 [cited 2023 May 5, 2023]; https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/who-when-to-vaccinate.html. Accessed 5 May 2023"},{"key":"2054_CR22","unstructured":"Koch-Institut R. Wissenschaftliche Begr\u00fcndung f\u00fcr die Aktualisierung der Empfehlungen zur Indikationsimpfung gegen Pneumokokken f\u00fcr Risikogruppen. 2016, Robert Koch-Institut, Epidemiologie und Gesundheitsberichterstattung."},{"key":"2054_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jim.2018.08.002","volume":"461","author":"DC LaFon","year":"2018","unstructured":"LaFon DC, Nahm MH. Measuring immune responses to pneumococcal vaccines. J Immunol Methods. 2018;461:37\u201343.","journal-title":"J Immunol Methods"},{"key":"2054_CR24","doi-asserted-by":"crossref","unstructured":"Siber GR, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816\u201326.","DOI":"10.1016\/j.vaccine.2007.01.119"},{"key":"2054_CR25","doi-asserted-by":"crossref","unstructured":"Andrews NJ, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14:839\u201346.","DOI":"10.1016\/S1473-3099(14)70822-9"},{"key":"2054_CR26","doi-asserted-by":"crossref","unstructured":"Tobudic S, et al. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PLoS ONE. 2012;7:e46133.","DOI":"10.1371\/journal.pone.0046133"},{"key":"2054_CR27","doi-asserted-by":"crossref","unstructured":"Goldblatt D. Conjugate vaccines. Clin Exp Immunol. 2000;119:1\u20133.","DOI":"10.1046\/j.1365-2249.2000.01109.x"},{"key":"2054_CR28","doi-asserted-by":"crossref","unstructured":"Rose MA, et al. Reference ranges and cutoff levels of pneumococcal antibody global serum assays (IgG and IgG2) and specific antibodies in healthy children and adults. Med Microbiol Immunol. 2013;202:285\u201394.","DOI":"10.1007\/s00430-013-0292-3"},{"key":"2054_CR29","doi-asserted-by":"crossref","unstructured":"Schauer U, et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Vaccine Immunol. 2003;10:202\u20137.","DOI":"10.1128\/CDLI.10.2.202-207.2003"},{"key":"2054_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plabm.2016.02.004","volume":"5","author":"AR Parker","year":"2016","unstructured":"Parker AR, Allen S, Harding S. Concentration of anti-pneumococcal capsular polysaccharide IgM, IgG and IgA specific antibodies in adult blood donors. Pract Lab Med. 2016;5:1\u20135.","journal-title":"Pract Lab Med"},{"key":"2054_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.697128","volume":"12","author":"A Robbins","year":"2021","unstructured":"Robbins A, et al. The 13-valent pneumococcal conjugate vaccine elicits serological response and lasting protection in selected patients with primary humoral immunodeficiency. Front Immunol. 2021;12: 697128.","journal-title":"Front Immunol"},{"key":"2054_CR32","doi-asserted-by":"crossref","unstructured":"Gerard AL, et al. Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE). Vaccine. 2020;38:6859\u201363.","DOI":"10.1016\/j.vaccine.2020.08.065"},{"key":"2054_CR33","unstructured":"Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol. 1986;63:127\u201334."},{"key":"2054_CR34","doi-asserted-by":"crossref","unstructured":"Cavaliere FM, et al. Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency. J Clin Immunol. 2013;33:838\u201346.","DOI":"10.1007\/s10875-012-9856-z"},{"key":"2054_CR35","doi-asserted-by":"crossref","unstructured":"Echeverr\u00eda de Carlos A, et al. Concentrations of pneumococcal IgA and IgM are compromised in some individuals with antibody deficiencies. J Immunoassay Immunochem. 2017;38:505\u201313.","DOI":"10.1080\/15321819.2017.1337641"},{"key":"2054_CR36","doi-asserted-by":"crossref","unstructured":"Janssen LMA, et al. The clinical relevance of IgM and IgA anti-pneumococcal polysaccharide ELISA assays in patients with suspected antibody deficiency. Clin Exp Immunol. 2021;205:213\u201321.","DOI":"10.1111\/cei.13605"},{"key":"2054_CR37","doi-asserted-by":"crossref","unstructured":"van der Linden M, Im\u00f6hl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLoS ONE. 2019;14:e0220453.","DOI":"10.1371\/journal.pone.0220453"},{"key":"2054_CR38","doi-asserted-by":"crossref","unstructured":"Silva-Costa C, et al. Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016&#x2013;2019). Microbiol Spectrum. 2022;10:e0107722.","DOI":"10.1128\/spectrum.01077-22"},{"key":"2054_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100409","volume":"18","author":"S Perniciaro","year":"2022","unstructured":"Perniciaro S, van der Linden M. Correction to \u201cPneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: a retrospective cohort study.\u201d Lancet Regi Health Europe. 2022;18:100409.","journal-title":"Lancet Regi Health Europe"},{"key":"2054_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.12659\/AOT.889536","volume":"18","author":"T Legris","year":"2013","unstructured":"Legris T, et al. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. Ann Transplant. 2013;18:622\u201334.","journal-title":"Ann Transplant"},{"key":"2054_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","volume":"16","author":"JCA Broen","year":"2020","unstructured":"Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16:167\u201378.","journal-title":"Nat Rev Rheumatol"},{"key":"2054_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/2010105818773773","volume":"28","author":"PV Licciardi","year":"2018","unstructured":"Licciardi PV, et al. Pneumococcal vaccination for HIV-infected individuals in Singapore. Proc Singap Healthc. 2018;28:55\u201360.","journal-title":"Proc Singap Healthc"},{"key":"2054_CR43","doi-asserted-by":"publisher","first-page":"15948","DOI":"10.1038\/s41598-021-95129-w","volume":"11","author":"GL Ignatova","year":"2021","unstructured":"Ignatova GL, Avdeev SN, Antonov VN. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study. Sci Rep. 2021;11:15948.","journal-title":"Sci Rep"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02054-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02054-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02054-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:05:47Z","timestamp":1700651147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02054-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2054"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02054-3","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any financial or non-financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University Hospital Essen, Germany (14\u20135858-BO).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}]}}